export default function IGF1LR3OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        IGF-1 LR3 is a modified version of IGF-1 &mdash; the growth factor your body produces in response to growth hormone &mdash; engineered to stay active for 20&ndash;30 hours instead of minutes. That extended duration amplifies the muscle-building signal and also the hypoglycemia risk, the cancer growth signaling, and every other effect IGF-1 produces. No pharmaceutical company is developing it for human clinical use, which is itself a meaningful signal.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Muscle-Building Person &mdash; serious about size, exploring the compound landscape</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I keep seeing IGF-1 LR3 mentioned in bodybuilding forums for serious muscle gains. Is it actually effective or mostly hype?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>IGF-1 is one of the main drivers of muscle growth &mdash; LR3 amplifies that signal</strong><br />Growth hormone works largely by making the liver produce IGF-1, which then drives muscle protein synthesis and growth. LR3 delivers that signal directly and keeps it active for most of a day, which is a potent anabolic input.</li>
          <li><strong>Community reports suggest real, measurable muscle gains</strong><br />IGF-1 LR3 has a long history in the bodybuilding community and user reports consistently describe significant size and fullness increases, particularly in the muscles trained shortly after injection. That experiential signal has persisted for decades.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The thing that makes it effective &mdash; the 20&ndash;30 hour half-life &mdash; is also what makes it more dangerous than regular IGF-1. Blood sugar drops can persist through the entire day and overnight, not just for an hour post-injection. Injecting fasted is how people end up unconscious. The same growth signal that builds muscle also stimulates cancer cell growth &mdash; if there is any undetected cancer, IGF-1 LR3 is the kind of compound that accelerates it. GH-axis peptides like ipamorelin and CJC-1295 achieve meaningfully similar anabolic results by working through the body&rsquo;s own regulation, with a substantially better risk profile. Net: the gains are real, but this is a compound where the risk/benefit calculation is genuinely unfavorable for most people, not just as a legal disclaimer.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Competitive Bodybuilder &mdash; advanced compounds, knows the risk landscape</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I understand the risks. What&rsquo;s the actual protocol picture &mdash; local injection vs. systemic, timing relative to training, dose range?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Local injection theory &mdash; muscle-specific growth signal</strong><br />IGF-1 LR3 is commonly injected directly into a trained muscle on the hypothesis that local delivery creates a more targeted growth signal in that tissue. Whether this produces meaningfully different results than systemic injection is not established scientifically, but it&rsquo;s the primary community protocol rationale.</li>
          <li><strong>Combination with GH and anabolic cycles &mdash; the axis stack</strong><br />At advanced levels, IGF-1 LR3 is used as part of a broader GH and hormone stack. The rationale is that exogenous GH and IGF-1 LR3 together saturate the entire GH/IGF-1 axis, producing a growth signal that neither alone provides as completely.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The local injection theory is plausible but not validated &mdash; IGF-1 LR3&rsquo;s 20&ndash;30 hour half-life means it circulates systemically regardless of injection site, which substantially weakens the local delivery rationale. Cancer screening before use is not optional for this compound &mdash; the IGF-1 receptor is overexpressed in multiple cancer types and is actively being targeted by oncology drugs. PSA for males, appropriate screening for your age and history. Running this without recent screening is accepting a risk you have not actually evaluated. Net: the protocol logic is followed by experienced bodybuilders with eyes open; it requires rigorous glucose monitoring throughout the half-life window, not just post-injection.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; GH/IGF-1 axis mechanistics, risk quantification</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The binding protein bypass is the key modification. What does the IGFBP resistance actually mean mechanistically for tissue-level signaling, and why isn&rsquo;t this in clinical development?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The IGFBP bypass reveals how the body normally regulates IGF-1 bioavailability</strong><br />Endogenous IGF-1 spends most of its time bound to binding proteins that limit how much free IGF-1 is available to activate receptors. LR3&rsquo;s resistance to those proteins means it circulates in its active, receptor-accessible form continuously &mdash; which is why the pharmacological effect is so different from the body&rsquo;s own IGF-1 even at similar circulating levels.</li>
          <li><strong>Understanding LR3 clarifies why the GH/IGF-1 axis has the safety profile it does</strong><br />The binding proteins are not redundant biology &mdash; they are the regulatory brake on a growth signal that, left unchecked, promotes cancer. LR3 removes that brake. Understanding exactly why that matters is necessary for understanding why GH-axis peptides that work through the body&rsquo;s own regulation are mechanistically safer.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The reason no pharmaceutical company is developing IGF-1 LR3 for clinical use is not regulatory inertia &mdash; it&rsquo;s that sustained free IGF-1R activation is the pharmacological mechanism that oncology is specifically trying to block. Oncology drugs targeting IGF-1R are in active development to treat cancer; using IGF-1 LR3 is activating the same receptor in the opposite direction, continuously, without the regulatory buffer of binding proteins. That is not a risk to dismiss by pointing to the anabolic benefit. For a biohacker building a GH-axis optimization protocol, physiological stimulation through ipamorelin and CJC-1295 achieves IGF-1 elevation within normal variation with feedback regulation intact &mdash; a substantially different risk posture. Net: mechanistically illuminating about the axis; practically, the risk/benefit case for human self-administration does not improve with deeper mechanistic understanding; it gets harder to justify.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What IGF-1 LR3 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a safer version of IGF-1 &mdash; the extended half-life makes hypoglycemia and cancer risk worse, not better</li>
              <li>Not a pharmaceutical-grade compound &mdash; no human clinical trials, no manufacturing standards</li>
              <li>Not appropriate for anyone with cancer history &mdash; this is the hardest stop on this compound</li>
              <li>Not appropriate for use while fasted &mdash; the hypoglycemia window is 12&ndash;24+ hours, not 1 hour</li>
              <li>Not a substitute for GH-axis peptides &mdash; ipamorelin and CJC-1295 achieve similar anabolic goals with a very different risk profile</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The IGFBP bypass reveals exactly how the body normally regulates free IGF-1 bioavailability</li>
              <li>Real anabolic effect &mdash; community use history consistently reports significant muscle growth</li>
              <li>Understanding LR3 clarifies why binding proteins exist as a regulatory brake on the growth axis</li>
              <li>The absence of pharmaceutical development is itself informative about how the oncology field views sustained free IGF-1R activation</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
